DIY: inexpensive workarounds to significantly enhance the bioavailability of lipophilic compounds like Urolithin A at home

#1

I want to get other people’s opinion on this (hopefully with more experience in chemistry and mixing):

Given the increasingly interesting news on Urolithin A, (The Stiffening Trap: How Aging Tissues Strangle Their Own Blood Supply ) I wanted to look into ways to improve its bioavailability.

Looking at all the Urolithin A studies (specifically the higher dose 50mg/kg to 300mg/kg dosing), Gemini mentioned:

Bioavailability Deficits: Raw, unformulated Urolithin A exhibits poor aqueous solubility and low natural bioavailability in animal intestines. Consequently, these high mg/kg values used in preclinical rodent studies are often required to achieve the systemic plasma concentrations that can be reached at much lower doses using modern micronized or lipid-encapsulated human delivery systems.

Gemini suggested:

The short answer is no, there are no authentic, high-efficiency “DIY” methods to produce true nano-micronized or nano-liposomal delivery systems at home using basic kitchen tools. The popular internet protocols—primarily using jewelry ultrasonic cleaning baths and soy lecithin—produce coarse macro-emulsions rather than true lipid-encapsulated nanoparticles.

However, there are highly practical, inexpensive chemical workarounds to significantly enhance the bioavailability of lipophilic compounds like Urolithin A (UA) at home without industrial equipment.

Pragmatic, High-Bioavailability DIY Workarounds

To bypass the need for industrial nanotech, you can exploit the lipophilic nature of the compound by creating a Simplified Self-Emulsifying Drug Delivery System (SEDDS) or utilizing mechanical wet-milling.

1. The SEDDS Lipid Carrier Proxy (Highest Efficiency)

Instead of trying to force a liposome to form in water, dissolve the compound directly into a lipid matrix that the human digestive tract absorbs via the lymphatic system (bypassing first-pass liver metabolism). Preclinical data indicates that submicron oil-in-water emulsions drastically improve UA baseline bioavailability.

  • The Carrier: Medium-Chain Triglyceride (MCT) oil or high-oleic sunflower oil.
  • The Emulsifier/Surfactant: Liquid sunflower lecithin or food-grade Polysorbate 80 (Tween 80).
  • The Protocol:
    1. Warm a measured volume of MCT oil gently (approx. 50–60°C / 122–140°F). Do not overheat, as polyphenols can degrade.
    2. Add the raw Urolithin A powder alongside 10–20% liquid lecithin by volume.
    3. Agitate vigorously (using a high-shear laboratory stirrer or a high-speed milk frother) until the crystalline powder is fully solubilized or uniformly suspended in the lipid phase.
  • Why it works: When this lipid mixture hits gastric fluids and bile salts, it spontaneously forms crude micellar structures and micro-emulsions in the gut, mimicking commercial lipid-encapsulation mechanics.

2. Low-Cost Wet Milling (Mechanical Micronization)

If you prefer a solid or powder format, you can manually reduce particle size to increase surface area, which accelerates the dissolution rate in the intestine.

  • The Protocol: Place the raw compound into a ceramic mortar and pestle. Add a few drops of absolute ethanol (99% food-grade) and a small amount of powdered lecithin to create a thick paste. Grind aggressively for 15–20 minutes as the solvent evaporates.
  • Why it works: The shear force mechanically breaks down larger crystalline aggregates (micronization), while the amphiphilic lecithin coats the newly sheared micro-crystals, preventing re-agglomeration and improving wettability when it enters the gastrointestinal tract.

Knowledge Gaps & Uncertainties

While these lipid-carrier and wet-milling methods optimize the kinetic environment for absorption, the exact peak serum concentration (Cmax​) and Area Under the Curve (AUC) achieved via home preparation remain unquantified. Without analytical validation tools like Dynamic Light Scattering (DLS) or High-Performance Liquid Chromatography (HPLC), the exact percentage of compound successfully solubilized or micronized vs. what remains unabsorbed can only be estimated based on broad pharmaceutical principles.

3 Likes
Grok comparison of Fisetin and D+Q
#2

Improved Bioavailability

Based on pharmacokinetic data evaluating lipid-based and submicron emulsion delivery systems for Urolithin A (UA), you can expect a 3-fold to 7-fold increase in systemic bioavailability (measured via plasma Area Under the Curve, or AUC) compared to unformulated, raw crystalline powder.

When transitioning from an isolated crystalline suspension to a Self-Emulsifying Drug Delivery System (SEDDS) or submicron emulsion proxy, the increase in oral absorption is driven by specific biochemical and physiological mechanisms:

Mechanisms Driving the Bioavailability Increase

  • Elimination of the Dissolution Rate Barrier: Urolithin A is classified under the Biopharmaceutics Classification System (BCS) as a low-solubility compound. In its raw crystalline state, its dissolution rate in gastric fluid is incredibly slow, meaning the majority of the powder passes through the tract unabsorbed. Pre-dissolving UA in a lipid matrix eliminates this initial rate-limiting step entirely.
  • Lymphatic Pathway Activation (First-Pass Bypass): Raw UA undergoes rapid and extensive Phase-II metabolism (glucuronidation and sulfation) in the enterocytes of the intestinal wall and the liver, converting the highly active aglycone into Urolithin A-glucuronide, which has significantly lower bioactivity. Utilizing an MCT and lecithin-based carrier promotes chylomicron formation, routing a fraction of the compound through the lymphatic system rather than the portal vein, thereby bypassing initial hepatic clearance.
  • Enhanced Intestinal Permeability: The inclusion of amphiphilic surfactants (like lecithin) lowers interfacial tension and mimics endogenous bile salt micelles. This allows the submicron lipid droplets containing the UA to interact more fluidly with the enterocyte membrane, facilitating passive transcellular absorption.

Pharmacokinetic Comparison Matrix

Formulation Type Estimated Bioavailability Increase (vs. Raw Powder) Primary Mechanism Technical Limitations
Raw Crystalline Powder Baseline (1X) Passive transport of dissolved fraction High fecal excretion; severe inter-individual variability based on microbiome status.
DIY SEDDS Proxy (MCT + Lecithin) 3X to 5X increase Spontaneous micelle formation; improved lipid-phase solubility Variable particle droplet size (macro to micro-emulsion range); highly dependent on digestive tract bile output.
Engineered Submicron Emulsions / Nanoparticles 6X to 7X increase Targeted receptor binding (e.g., transferrin); controlled nanometer droplet size Requires industrial high-pressure microfluidization or probe sonication.

Knowledge Gaps & Limitations of the Proxy Method

While a crude SEDDS or lipid carrier drastically outperforms raw powder, several variables remain unquantified without laboratory testing:

  1. Droplet Size Instability: An industrially prepared submicron emulsion relies on specific synthetic surfactants (such as Polysorbate 80 or Kolliphor EL) to maintain a thermodynamic droplet equilibrium below 200 nm. A DIY mixture utilizing native sunflower lecithin will yield a broader particle size distribution, meaning a portion of the mixture will behave like a standard macro-emulsion, achieving lower systemic delivery than optimized nano-formulations.
  2. The Aglycone vs. Glucuronide Ratio: It is currently unknown exactly what percentage of a home-brewed lipid mixture successfully evades first-pass glucuronidation via the lymphatic system versus standard portal vein absorption. While overall plasma concentration ($C_{max}$) increases, the exact ratio of free UA to its less active conjugated metabolites will vary based on individual metabolic rates and the exact lipid composition used.
#3

Wouldn’t fenugreek be a good addition? Its formation of a hydrogel scaffold, extending time available for absorption in the stomach and small intestine, would seem to work with any lipophilic supplement, as in the fisetin DIY FF-20.

#4

Perpetual Life offers 30 servings of 1000 mg per serving with a liposomal delivery system for $50 per month. Free shipping, third-party testing, etc.

https://perpetualife.bio/products/urolithin-a

Innerbody Research, in a review for internet consumption, compared it to Mitopure and Codeage. If I were on the verge, I’d buy the capsules and save the DIY for a cream.

1 Like
#5

My impression is that RapAdmin was trying to get suggestions of a general nature from someone here with that kind of expertise - workarounds that could be used with many supplements. Certainly interested in urolithin A, but using it as an example, like he did with fisetin in that thread. Thanks for the reference. Good to see a lower price, but for now, it would still seem a good candidate for a DIY attempt.

1 Like
#6

The simplest would be to eat it with a meal with 10-20 grams of fat…that would stimulate bile release and enhance absorption. Yogurt with nuts or almond butter for instance.
I think the challenge with a DIY approach is you don’t really know if it will work or help…whatever approach you use “should” help but there’s no data.
The clinical trials that do exist were using doses in the 500-1000 mg/day and they did have biological effects so it does have some absorption and positive effects without heroic dosing efforts. Are you trying to get more on board?

1 Like
#7

My review of the studies on Urolithin A suggests there may be significantly more benefit at higher doses (see research below), but its obvious that Timeline / Nestle is maximizing revenue with high prices at 500mg per day, so financially it doesn’t make sense to try the higher doses. I use rapamycin as my guide… large and well validated longevity benefits and a cost (to me, typically) of around $30 to $40 per month. When supplements with much less validation and benefits are charging more… I look for ways to get around those higher prices. And, the bioavailability of Urolithin A is not great, so improving that through any methods seems like a good thing to try, though the lack of any way to validate the actual benefits / bioavailability increases is a huge issue.

Urolithin A , Higher Dose Research:

A systematic review of the literature on the gut-microbiota metabolite Urolithin A (UA) identifies several key rodent studies utilizing high-dose oral interventions within the 100 to 300 mg/kg/day range.

The primary peer-reviewed papers meeting these exact parameters evaluate UA across cognitive decline, organ injury, and metabolic dysfunction models:

1. Neuroinflammation & Cognitive Decline (300 mg/kg/day)

  • Study Focus: Evaluating the neuroprotective capacity of UA in a transgenic mouse model of Alzheimer’s disease.
  • Dosing Regimen: APP/PS1 mice (28 weeks old) were orally administered 300 mg/kg/day of UA dissolved in 0.5% carboxymethylcellulose (CMC) for 14 consecutive days.
  • Key Findings: High-dose UA successfully crossed the blood-brain barrier to ameliorate spatial learning and memory deficits (measured via Morris water maze), significantly reduce neuronal apoptosis in the cortex and hippocampus, and suppress amyloid-beta (Aβ) plaque deposition along with peri-plaque microgliosis.
  • Source: Gong et al., 2019

2. Hyperuricemic Nephropathy & Mitophagy (100 mg/kg/day)

  • Study Focus: Investigating the protective effects of UA on fructose-induced kidney damage and hyperuricemia (gout models).
  • Dosing Regimen: Fructose-fed mice were administered UA via daily intragastric gavage at a low dose (50 mg/kg/day) and a high dose (100 mg/kg/day) for a duration of 8 weeks.
  • Key Findings: The 100 mg/kg/day cohort showed a pronounced reduction in serum uric acid, creatinine, and blood urea nitrogen (BUN). Mechanistically, this dose attenuated renal oxidative stress and suppressed the STING-NLRP3 inflammatory cascade by restoring Parkin-dependent mitophagy.
  • Source: Zhang et al., 2022

3. Accelerated Aging & Organ Protection (100 to 150 mg/kg/day)

  • Study Focus: Assessing tissue-protective, anti-apoptotic, and antioxidant effects of UA against chemical-induced systemic aging.
  • Dosing Regimen: D-galactose-treated aging mice were given escalating oral doses of UA at 50, 100, and 150 mg/kg/day for 8 weeks.
  • Key Findings: Doses at and above 100 mg/kg/day significantly mitigated D-gal-induced liver and kidney injuries. The intervention lowered serum ALT, AST, and BUN levels while modulating apoptotic markers (decreasing Bax and cleaved caspase-3 while increasing Bcl-2 expression).
  • Source: Chen et al., 2020

Methodological & Translational Context

When analyzing these papers, two critical factors should be taken into account regarding the 100–300 mg/kg/day animal dosing bracket:

  1. Human Equivalent Dose (HED) Translation: Applying the standard FDA body surface area normalization formula (HED=Animal Dose×Human Km​Animal Km​​), a mouse dose of 100 to 300 mg/kg translates to a human equivalent range of approximately 8.1 to 24.3 mg/kg. For a 70 kg human, this equates to roughly 570 to 1,700 mg/day—aligning precisely with the upper bounds tested in human safety trials (typically capped at 500 mg to 1,000 mg/day in clinical settings).
  2. Bioavailability Deficits: Raw, unformulated Urolithin A exhibits poor aqueous solubility and low natural bioavailability in animal intestines. Consequently, these high mg/kg values used in preclinical rodent studies are often required to achieve the systemic plasma concentrations that can be reached at much lower doses using modern micronized or lipid-encapsulated human delivery systems.
#8

That is with all the products.they sell.

#9

Perhaps, but this is the only Nestle product I’m interested in :wink:

#10

You purchase Nestlé products knowing or unknowing, they are world’s largest food and beverage company

#11

RapAdmin, I think you have your dosing equivalents up.

100mg/kg/day for a mouse is roughly 570 mgs for a 70kg human. This is well within the 500-1000 mg/day dosing used in clinical trials. 300mg/kg for a mouse is 1.7gram so above but not much higher.

I realize I am one of the more critical and cautious posters on the forum but I would have some concern at taking any compound at 1.7 grams per day chronically, eg, every day. Here’s a recent clinical report showing kidney stones from urolithin A for instance and the authors question whether we might see more as people ramp up their usage.

Kidney Int Rep 2026 Mar 27;11(6):106515.

doi: 10.1016/j.ekir.2026.106515. eCollection 2026 Jun.

First Reported Human Cases of Urolithin A Renal Calculi

Sara L Best 1 2, Valentinas Gruzdys 2, Mark White 3, Natalia Gromadzka 2, Benjamin Owen 4, Yongbo Zhang 4, John R Asplin 2

3 Likes
#12

https://www.kireports.org/article/S2468-0249(26)02747-6/fulltext

Dietary and medication history was available from 6 patients. All 6 patients reported consuming walnuts daily or nearly daily, often in “smoothies,” patients created to promote health. Other potential ULA exposures these patients reported included blueberries (daily: 2, occasionally: 2), strawberries (occasional), almonds or almond milk (frequently: 2), and 1 consumed pomegranate rarely. Over-the-counter supplements were reviewed with these 6 patients, and none were taking ULA supplements.

Pt ID M/F Specimen date Age Source Stone weight Stone composition ULA exposure
ULA 1 F 1/24 76 Kidney 1039 mg 50% ULA, 50% COM Blueberry and walnut smoothie daily
ULA 2 F 3/24 67 n/a 33 mg 30% ULA, 70% COM Walnuts frequently, seasonal blueberries and pomegranate
ULA 3 M 5/24 85 Bladder 120 mg 40% ULA, 50% COM, 10% CaPhos Blueberry, walnut, and almond milk smoothie daily, seasonal strawberries
ULA 4 F 6/24 87 Ureter 1 mg 80% ULA, 20% COM Walnuts and almonds nearly daily smoothie, occasional blueberries
ULA 5 F 10/24 71 Kidney 162 mg 5% ULA, 75% COM, 20% COD Walnuts daily, occasional blueberries and strawberries
ULA 6 F 11/24 72 Kidney 1356 mg 10% ULA, 50% COM, 40% COD Daily walnuts
ULA 7 F 12/24 59 n/a 895 mg 10% ULA, 60% COM, 20% COD, 10% CaPhos n/a
ULA 8 F 12/24 74 Kidney 75 mg 5% ULA, 85% COM, 10% COD n/a
#13

Chemistry was my worst subject. So from ignorance I ask: why not just take a liposomal form of Urolithin A with a fat-containing meal?

#14

Yes, I saw this JuanDaw…the fact that these patients got UA containing kidney stones just from regular dietary sources and no supplementation of pure UA is potentially concerning and something to keep an eye on.

#15

The paper hazards an explanation; and the problem may not be the ULA.

ULA is extensively metabolized in the gut, with glucuronidated and sulfated metabolites appearing in blood and urine at ∼ 100-fold and ∼ 10-fold higher levels than the native molecule, respectively.9 These metabolites are more soluble and none have been detected in ULA stones we analyzed. Perhaps patients who form ULA stones from foods alone may have both a ULA-producing gut microbiome and impaired metabolic conjugation, leading to high urinary levels of poorly soluble, unconjugated or free ULA.

From the table above, the ones with high ULA (50% and 40%) take walnut smoothies. The ones who eat walnuts directly have ULA at 30, 5, and 10%). Walnuts needed to make a smoothie (3/4 cup - see recipe below) are more than the handful needed for snacking. The outlier is the one taking walnut and almond smoothies (80% ULA).

As for almonds, they are heavy on oxalates (added to walnuts which are medium heavy on oxalates).

This is a severely underpowered study (n=6) to make any conclusions. Even on the merits of the paper, it seems that the kidney stones are more a problem of metabolism, as the authors explain above, .rather than the ULA itself.

1 Like
#16

Yes but if more people start taking ULA and a certain percentages of them are “poor metabolizers”, eg, do not form the glucoronidated or sulfated metabolites, we will start seeing more ULA containing stones.

I agree, though, more studies are needed. It’s an N=8 so yes, underpowered but its what this diagnostic facility had received.

"In 2024 the Labcorp calculi composition analysis facility began receiving urinary stones from multiple patients that contained an unidentified compound not included on our infrared (IR) spectral library and had not been previously reported as a component of human urolithiasis. All stones contained either calcium oxalate or calcium phosphate salts in addition to the unknown compound (Supplementary Figure S1). "

1 Like
#17

If your concern is oxalates, used raw almonds that are sprouted.

Review the following;

AI-generated answer.

Please verify critical facts.

'Research indicates that sprouting (or extended soaking which mimics sprouting conditions) reduces oxalate levels in almonds by 6.7% to 20% after 12–18 hours, with 48 hours of soaking producing a greater drop than 24 hours. However, most commercially available raw almonds in the U.S. are pasteurized, which kills the germ and prevents actual germination , meaning they cannot truly sprout even if soaked. For those seeking genuine sprouting, unpasteurized almonds sourced from Europe or small domestic suppliers are required, and extended soaking still provides oxalate reduction even without visible sprouts."

AI-generated answer.

Please verify critical facts.

And

Certified Organic Raw Unpasteurized Almonds

https://www.heronfoxfarm.com/